A Phase-I/II, Open Label, Dose-Finding Study of DO-013 Alone and In Combination with Gemcitabine Among Patients with Advanced Carcinoma of Pancreas

Trial Profile

A Phase-I/II, Open Label, Dose-Finding Study of DO-013 Alone and In Combination with Gemcitabine Among Patients with Advanced Carcinoma of Pancreas

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 Aug 2016

At a glance

  • Drugs DO 013 (Primary) ; Gemcitabine (Primary)
  • Indications Pancreatic cancer
  • Focus Adverse reactions; First in man
  • Sponsors Cadila Pharmaceuticals
  • Most Recent Events

    • 30 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top